Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting

Huntington Beach, California and Amsterdam, June 4, 2010 (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics, today
announced that researchers from Agendia and leading academic centers
in the U.S. and Europe will present data from multiple studies
concerning Agendia's assays MammaPrint(R), BluePrint(TM), and
ColoPrint(TM) at the American Society of Clinical Oncology Annual
Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint,
the company's lead product, is the only FDA-cleared breast cancer
recurrence test. FDA clearance requires clinical and analytical
validation and full transparency to ensure patient safety issues are
addressed. The company anticipates launching its prognostic colon
cancer test ColoPrint in late 2010.

The study results underpin the broad predictive and prognostic
power of MammaPrint and highlight prospective and independently
validated data on ColoPrint. Visitors can meet the Agendia team in
booth #18018 and study results will be discussed at the following
sessions:

Breast Cancer
Date: Saturday, June 5, 2010
POSTER PRESENTATION - Abstract #10615
Substratification of 70-gene high-risk breast cancers with a
validated 80-gene molecular subtyping profile
F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas
Time: 8:00 AM - 12:00 PM
Location: S Hall A2
Date: Saturday, June 5, 2010
POSTER PRESENTATION - Abstract # 540
Gene signatures as predictors of response to neoadjuvant
chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC),
or AC and nab-paclitaxel (nab-P) and carboplatin plus or minus
trastuzumab in patients (pts) with stage II-III and inflammatory breast
cancer (IBC)
G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L.
Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender
Time: 2:00 PM - 6:00 PM
Location: S Hall A2
Date: Saturday, June 5, 2010
POSTER PRESENTATION - Abstract # 561
Evaluation of the 70-gene prognosis MammaPrint signature for
the prediction of prognosis of breast cancer independently from
histologic grade
M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't
Veer
Time: 2:00 PM - 6:00 PM
Location: S Hall A2
Date: Monday, June 7, 2010
POSTER DISCUSSION - Abstract # 1520
Effect of screening on the detection of good and poor
prognosis breast cancers
Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S.
Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer
Time: 2:00 PM - 6:00 PM / 5:00 PM - 6:00 PM (discussion in
E451b)
Location: E450b
Colon Cancer
Date: Monday, June 7, 2010
POSTER PRESENTATION - Abstract # TPS199
The PARSC trial, a prospective study for the assessment of
recurrence risk in stage II colon cancer (CC) patients using ColoPrint
R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke
Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg
Time: 8:00 AM - 12:00 PM
Location: S Hall A2
Date: Tuesday, June 8, 2010
POSTER DISCUSSION - Abstract # 3513
Independent validation of a prognostic genomic profile (ColoPrint) for
stage II colon cancer (CC) patients
R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I.
Simon, K. Janssen, H. Friess
Time: 11:00 AM - 12:00 PM
Location: S 406 (Vista Room)

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
under the in vitro diagnostic multivariate index assay (IVDMIA)
guidelines requires clinical and analytical validation and reporting
systems to ensure patient safety issues are addressed. Highly
accurate, MammaPrint identifies patients with early metastasis risk -
patients who are likely to develop metastases within five years
following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear
rationale to assess the benefit of chemotherapy in addition to other
clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited
and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. Agendia is based in Huntington Beach, California, and in
Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: MEDIA CONTACTS: Hans Herklots, Agendia, +31-20-462-1557
Office,+31-620-083-509 Mobile, hans.herklots@agendia.com; Valerie
Delva, RicochetPublic Relations, +1-212-679-3300 x128 Office,
+1-917-755-6194 Mobile,vdelva@ricochetpr.com